Takeda Pharmaceutical Company Limited announced today that an additional indication of concomitant therapy with insulin for ACTOS (pioglitazone hydrochloride), a medicine for the treatment of type 2 diabetes, was approved on March 24 by the Ministry of Health, Labour and Welfare.
The details can be read here.
No comments:
Post a Comment